<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ponesimod: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ponesimod: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ponesimod: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="131189" href="/d/html/131189.html" rel="external">see "Ponesimod: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55648664"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ponvory;</li>
<li>Ponvory Starter Pack</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56421840"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ponvory;</li>
<li>Ponvory Initiation Pack</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55629085"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Sphingosine 1-Phosphate (S1P) Receptor Modulator</li></ul></div>
<div class="block doa drugH1Div" id="F55680811"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Cardiac monitoring</b>: First-dose 4-hour monitoring is recommended for patients with certain preexisting cardiac conditions, including sinus bradycardia (heart rate &lt;55 bpm), first- or second-degree (Mobitz type 1) atrioventricular block, or a history of myocardial infarction or heart failure ≥6 months prior to initiation. For these patients, administer the first dose and doses following therapy interruption (≥4 days) in a setting in which resources to appropriately manage symptomatic bradycardia and other conduction abnormalities are available. <b>Infection: </b>Delay initiation of therapy in patients with active infection. In high-risk populations or in countries with high tuberculosis (TB) burden, screen for latent infections (eg, hepatitis, TB) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing</b>: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i> Administer once daily according to the following 14-day dose titration:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Ponesimod Initial Dosage Titration</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Day of therapy</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">1 and 2</p></td>
<td align="center">
<p style="text-indent:0em;">2 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 and 4</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5 and 6</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8</p></td>
<td align="center">
<p style="text-indent:0em;">6 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">9</p></td>
<td align="center">
<p style="text-indent:0em;">7 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11</p></td>
<td align="center">
<p style="text-indent:0em;">9 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">12, 13, and 14</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 and thereafter</p></td>
<td align="center">
<p style="text-indent:0em;">20 mg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance</i>: 20 mg once daily, beginning on day 15.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>≤3 consecutive doses missed:</i> If during titration, resume with the first missed titration dose, and resume the titration schedule at that dose and titration day. If during maintenance, resume treatment with the maintenance dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>≥ 4 consecutive doses missed</i>
<b>: </b>Reinitiate treatment with day 1 of the initial titration regimen, including first-dose monitoring when appropriate.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy</b>: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F55681938"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F55681939"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment (Child-Pugh class B or C): Avoid use.</p></div>
<div class="block doe drugH1Div" id="F55681937"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F56180155"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Transient, dose dependent decreases in heart rate, <b>bradycardia</b>, and <b>sinus bradycardia</b> (HR &lt;50 bpm) have been observed primarily following the first dose of ponesimod and with dose titration. Transient atrioventricular (AV) conduction delays, manifesting as <b>first-degree AV block</b>, have also been observed with initiation of therapy. Second- and third-degree AV blocks have occurred with other sphingosine 1-phosphate (S1P) receptor modulators. In addition, <b>hypertension</b> has commonly been reported with ponesimod.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Ponesimod is a selective S1P receptor modulator; S1P receptors play a role in regulating vascular tone, heart rate, and cardiac repolarization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24659797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24659797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Bradycardia/decreased heart rate: Dose-related; S1P modulators have been associated with negative chronotropic effects; however, these effects may attenuate over time secondary to S1P desensitization on atrial myocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26770667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26770667'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Bradycardia/decreased heart rate: Rapid; following the first dose, onset typically begins within 1 hour postdose, with maximal decrease usually occurring ~2 to 4 hours postdose. Following day 1, decreases in heart rate are typically less pronounced.</p>
<p style="text-indent:-2em;margin-left:6em;">Hypertension: Delayed; increased BP occurred ~1 month after initiation of therapy and persisted with continued treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Bradycardia/AV conduction delays: Preexisting conditions that may increase the risk for bradycardia or AV block; concurrent therapy with medications that decrease heart rate. Of note, contraindications related to these risk factors exist.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cutaneous malignancies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Basal cell carcinoma</b> and other skin malignancies (including <b>malignant melanoma</b> and <b>squamous cell carcinoma </b>of the skin) have occurred rarely with ponesimod.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting skin cancer (potential risk factor)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum transaminases</b> have been observed with ponesimod therapy, primarily as <b>increased serum alanine aminotransferase</b> (ALT), including increases up to 5 x ULN. Most ALT increases ≥3 x ULN were single transient asymptomatic events that resolved spontaneously or resulted in discontinuation of therapy (per trial protocol) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32708516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32708516'])">Ref</a></span>). The majority of patients with ALT increases ≥3 x ULN continued treatment, with values decreasing to ALT &lt;3 x ULN within ~2 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; median time to development of ALT ≥3 x ULN was 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of significant liver disease (potential risk factor)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lymphocytopenia/Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reversible <b>lymphocytopenia</b> occurs during ponesimod therapy. <b>Infection</b> is commonly observed with use, typically <b>upper respiratory tract infection</b> and less commonly <b>urinary tract infection</b>; <b>viral infections</b> (eg, <b>herpes virus infection</b>) have also been observed. Infections may be serious, life-threatening, and potentially fatal. Fatal cryptococcal meningitis, disseminated cryptococcal infection, and progressive multifocal leukoencephalopathy have been reported with other sphingosine 1-phosphate (S1P) receptor modulators.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; as an antagonist of the sphingosine 1-phosphate 1 receptor (S1P<sub>1R</sub>), ponesimod results in the blocking of S1P1R receptors on lymphocytes, a necessary signal for their release from peripheral lymphoid organs, causing a reduction in number of circulating lymphocytes. Sequestered lymphocytes remain in peripheral lymphoid organs preventing their movement to sites of inflammation where they would typically contribute to immune-mediated pathology (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24659797','lexi-content-ref-31214480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24659797','lexi-content-ref-31214480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; a single oral dose reduced circulating lymphocytes in a rapidly reversible manner; continued dosing results in a maximum effect within 7 to 14 days for each dose level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24659797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24659797'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Macular edema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Macular edema</b> has occurred with ponesimod therapy. Though the incidence is rare, macular edema is also associated with other sphingosine 1-phosphate receptor modulators.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of uveitis</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Progressive multifocal leukoencephalopathy and sequelae</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients taking sphingosine 1-phosphate (S1P) receptor modulators. Symptoms may include progressive weakness on one side of the body or clumsiness of limbs, vision disturbances, and mental status changes. Immune reconstitution inflammatory syndrome (IRIS) has been reported in patients who discontinued S1P receptor modulator therapy due to developing PML and can result in a rapid decline in patient condition, including characteristic changes on MRI, neurological symptoms, and death.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>An opportunistic viral infection of the brain caused by the John Cunningham (JC) virus.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>PML: Symptoms progress over days to weeks. IRIS: Occurred within a few months after discontinuation in most cases.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (general):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Use in immunocompromised patients</p>
<p style="text-indent:-2em;margin-left:6em;">• Polytherapy with immunosuppressants</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Respiratory effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduced forced expiratory volume</b> over 1 second (FEV1) and reductions in diffusion lung capacity for carbon monoxide have occurred with ponesimod therapy. There is insufficient evidence to determine whether changes in FEV1 or decrease in forced vital capacity are reversible with drug discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; mechanism is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; mostly occurred in the first month after therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Severe respiratory disease (eg, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55646357"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≥5 x ULN: 5%; ≥3 x ULN: 17%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Alanine Aminotransferase table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-alanine-aminotransferase" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-alanine-aminotransferase')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Serum Alanine Aminotransferase</span>, increased serum transaminases (23%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Transaminases table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-transaminases" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-transaminases')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Transaminases</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Alanine Aminotransferase" frame="border" id="lexi-content-increased-serum-alanine-aminotransferase" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Increased Serum Alanine Aminotransferase</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥3 x ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥5 x ULN</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Transaminases" frame="border" id="lexi-content-increased-serum-transaminases" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Increased Serum Transaminases</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (54%; serious or severe infection: 2%)<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 3</a>)</span><span class="table-link" style="display:none;">Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">54%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">52%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Serious or severe infection</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (37%)<span class="lexi-table-link-container"> (<a aria-label="Upper Respiratory Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-upper-respiratory-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-upper-respiratory-tract-infection')">table 4</a>)</span><span class="table-link" style="display:none;">Upper Respiratory Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Upper Respiratory Tract Infection" frame="border" id="lexi-content-upper-respiratory-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Upper Respiratory Tract Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (≤6%)<span class="lexi-table-link-container"> (<a aria-label="Bradycardia table link" class="lexi-table-link" data-table-id="lexi-content-bradycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bradycardia')">table 5</a>)</span><span class="table-link" style="display:none;">Bradycardia</span>, chest discomfort (≥2%), first degree atrioventricular block (3%)<span class="lexi-table-link-container"> (<a aria-label="First Degree Atrioventricular Block table link" class="lexi-table-link" data-table-id="lexi-content-first-degree-atrioventricular-block" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-first-degree-atrioventricular-block')">table 6</a>)</span><span class="table-link" style="display:none;">First Degree Atrioventricular Block</span>, hypertension (10%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 7</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, peripheral edema (≥2%), sinus bradycardia (≤6%)<span class="lexi-table-link-container"> (<a aria-label="Sinus Bradycardia table link" class="lexi-table-link" data-table-id="lexi-content-sinus-bradycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sinus-bradycardia')">table 8</a>)</span><span class="table-link" style="display:none;">Sinus Bradycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bradycardia" frame="border" id="lexi-content-bradycardia" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Bradycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bradycardia at treatment initiation</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="First Degree Atrioventricular Block" frame="border" id="lexi-content-first-degree-atrioventricular-block" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: First Degree Atrioventricular Block</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sinus Bradycardia" frame="border" id="lexi-content-sinus-bradycardia" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Sinus Bradycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sinus bradycardia on ECG (defined as HR less than 50 bpm)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (2%), hyperkalemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (≥2%), xerostomia (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (6%)<span class="lexi-table-link-container"> (<a aria-label="Urinary Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-urinary-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-urinary-tract-infection')">table 9</a>)</span><span class="table-link" style="display:none;">Urinary Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Urinary Tract Infection" frame="border" id="lexi-content-urinary-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Urinary Tract Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: C-reactive protein increased (2%), lymphocytopenia (≤3%, including severe lymphocytopenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes virus infection (5%)<span class="lexi-table-link-container"> (<a aria-label="Herpes Virus Infection table link" class="lexi-table-link" data-table-id="lexi-content-herpes-virus-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-herpes-virus-infection')">table 10</a>)</span><span class="table-link" style="display:none;">Herpes Virus Infection</span>, herpes zoster infection (&lt;2%), viral infection (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Herpes Virus Infection" frame="border" id="lexi-content-herpes-virus-infection" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Herpes Virus Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (≥2%), dizziness (5%), drowsiness (3%), fatigue (≥2%), insomnia (≥2%), migraine (≥2%), seizure (1%), vertigo (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (≥2%), joint swelling (≥2%), limb pain (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Macular edema (1%)<span class="lexi-table-link-container"> (<a aria-label="Macular Edema table link" class="lexi-table-link" data-table-id="lexi-content-macular-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-macular-edema')">table 11</a>)</span><span class="table-link" style="display:none;">Macular Edema</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Macular Edema" frame="border" id="lexi-content-macular-edema" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Macular Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (4%), dyspnea (5%), rhinitis (≥2%), sinusitis (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Basal cell carcinoma of skin<span class="lexi-table-link-container"> (<a aria-label="Basal Cell Carcinoma of Skin table link" class="lexi-table-link" data-table-id="lexi-content-basal-cell-carcinoma-of-skin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-basal-cell-carcinoma-of-skin')">table 12</a>)</span><span class="table-link" style="display:none;">Basal Cell Carcinoma of Skin</span>, malignant melanoma</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Basal Cell Carcinoma of Skin" frame="border" id="lexi-content-basal-cell-carcinoma-of-skin" rules="all">
<caption style="text-align:center;">
<b>Ponesimod: Adverse Reaction: Basal Cell Carcinoma of Skin</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Teriflunomide)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ponesimod)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Teriflunomide)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">565</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">566</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Respiratory: Reduced forced expiratory volume (dose dependent)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hematologic &amp; oncologic: Squamous cell carcinoma of the skin</p></div>
<div class="block coi drugH1Div" id="F55629088"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months; presence of Mobitz type II second-degree, third-degree atrioventricular block, or sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to ponesimod or any component of the formulation; patients at risk for opportunistic infections, including those immunocompromised due to treatment (eg, antineoplastic, immunosuppressive, or immunomodulating therapies; total lymphoid irradiation; bone marrow transplantation) or disease (eg, immunodeficiency syndrome); patients with active bacterial, fungal, or viral (eg, hepatitis, tuberculosis) infections; patients with active malignancy (except basal cell carcinoma of the skin); moderate or severe hepatic impairment; pregnancy; patients of childbearing potential not using highly effective birth control.</p></div>
<div class="block war drugH1Div" id="F55678027"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Posterior reversible encephalopathy syndrome (PRES) has occurred with S1P receptor modulators. Symptoms are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delayed diagnosis and treatment may result in permanent neurological sequelae. Discontinue use if PRES is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use is not recommended in patients with a history of cardiac arrest, cerebrovascular disease (eg, transient ischemic attack, stroke occurring &gt;6 months prior to treatment initiation), uncontrolled hypertension, or severe untreated sleep apnea, as bradycardia may be poorly tolerated; obtain cardiologist consultation prior to therapy initiation in these patients. Cardiologist consultation should also be obtained prior to initiation in patients with significant QT prolongation (≥500 msec), atrial flutter/fibrillation or arrhythmia treated with a class Ia or III antiarrhythmic, unstable ischemic heart disease, decompensated cardiac failure occurring ≥6 months prior to therapy initiation, history of Mobitz Type II second degree or higher AV block, sick sinus syndrome, sinoatrial heart block, recurrent syncope, or symptomatic bradycardia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppressive or immune-modulating therapy: Initiating therapy following alemtuzumab treatment is not recommended. Treatment initiation following prior immunosuppressive or immune-modulating therapy may result in unintended additive immunosuppressive effects; half-life and mechanism of action of prior therapy should be taken into consideration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Severe exacerbation of disease and disease rebound has occurred following discontinuation of S1P receptor modulators. Monitor for development of immune reconstitution inflammatory syndrome in the setting of progressive multifocal leukoencephalopathy and severe increase in disability following discontinuation and begin appropriate treatment as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Vaccinations may be less effective if administered during treatment with ponesimod. Complete necessary live-attenuated vaccine immunization at least 1 month prior to initiation of therapy. Avoid live-attenuated vaccines in patients who currently receive or have discontinued ponesimod within the last 1 to 2 weeks; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]). Prior to initiation of therapy, test for VZV antibodies in patients without a health care professional–confirmed history of varicella (chickenpox) or without documentation of a full course of vaccination. Provide a full course of VZV vaccination prior to initiation of therapy in VZV antibody–negative patients; delay initiation of therapy for 4 weeks following VZV vaccination.</p></div>
<div class="block foc drugH1Div" id="F55648665"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ponvory: 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ponvory Starter Pack: 2 mg, 3 mg, 4 mg (two each); 5 mg, 6 mg, 7 mg, 8 mg, 9 mg (one each); 10 mg (three each) (14 ea)</p></div>
<div class="block geq drugH1Div" id="F55648663"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55670736"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Ponvory Starter Pack Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-3-4-5-6-7-8-9&amp; 10 MG (per each): $364.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ponvory Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $364.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56421841"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ponvory: 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ponvory Initiation Pack: 2 mg, 3 mg, 4 mg (two each); 5 mg, 6 mg, 7 mg, 8 mg, 9 mg (one each); 10 mg (three each) (14 ea)</p></div>
<div class="block adm drugH1Div" id="F55681940"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Swallow tablets whole.</p></div>
<div class="block hazard drugH1Div" id="F55771992"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Ponesimod may cause teratogenicity, reproductive toxicity, and has a structural or toxicity profile similar to an existing hazardous agent.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F55678016"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:-2em;margin-left:2em;">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Ponvory: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F213498s004lbl.pdf%23page%3D30&amp;token=n4bCaaSpABxKGMiPjfOFGHGbbnJtFM9MrsRSaj%2FLWrGzP1N2V7GbNUvcv7NMZQTDjMwfHmuamLtCUBm5%2BBN%2F%2BcEjgBp%2Fgt%2FLOiOlQwEFsPc8nd%2FNGwcD1GvLzEOs4XMU&amp;TOPIC_ID=131158" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213498s004lbl.pdf#page=30</a></p></div>
<div class="block use drugH1Div" id="F55629087"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Multiple sclerosis, relapsing:</b> Treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.</p></div>
<div class="block cyt drugH1Div" id="F55677980"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2J2 (minor), CYP3A4 (minor), UGT1A1, UGT2B7; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F55677977"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: Ponesimod may enhance the immunosuppressive effect of Alemtuzumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of Ponesimod. Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): Sphingosine 1-Phosphate (S1P) Receptor Modulator may enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the immunosuppressive effect of Sphingosine 1-Phosphate (S1P) Receptor Modulator.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A1 Inducers: May decrease the serum concentration of Ponesimod.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55678018"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who may become pregnant should use effective contraception during therapy and for 1 week after the last ponesimod dose.</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy, except in patients at high risk of MS activity (AAN [Rae-Grant 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Consider use other agents in patients at high risk of disease reactivation who are planning to become pregnant. Delaying pregnancy is recommended for patients with persistent high disease activity; when disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F55678019"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to ponesimod may cause fetal harm. Ponesimod acts on the sphingosine 1-phosphate receptor, a receptor involved in embryogenesis, including vascular and neural development.</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in patients at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block brc drugH1Div" id="F55678020"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ponesimod is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F55681942"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>All patients:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CBC including lymphocyte count (baseline [within 6 months or after discontinuation of previous multiple sclerosis therapy]).</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic monitoring: Bilirubin and transaminase levels (baseline [within 6 months]); transaminases in patients who develop symptoms of hepatic dysfunction (as clinically necessary).</p>
<p style="text-indent:-2em;margin-left:4em;">ECG (baseline) and BP (as clinically indicated); ophthalmologic exam of fundus, including macula (at baseline and if vision changes; more frequent in patients with diabetes or a history of uveitis), respiratory function (FEV<sub>1</sub>) (as clinically indicated), latent infection screening (eg, hepatitis, tuberculosis [TB]) in high-risk populations or in countries with high TB burden (baseline); varicella-zoster virus (VZV) antibodies (prior to starting treatment in patients with no health care professional–confirmed history of chickenpox or without documented previous full series VZV vaccination), signs and symptoms of infection (during treatment and at least 1 to 2 weeks after discontinuation), signs/symptoms of progressive multifocal leukoencephalopathy, immune reconstitution inflammatory syndrome (IRIS), and/or posterior reversible encephalopathy syndrome; skin examination and monitoring for suspicious skin lesions (periodically); severe increase in disability following discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional required monitoring for patients with sinus bradycardia (heart rate &lt;55 bpm), first- or second-degree (Mobitz type 1) atrioventricular block, or a history of myocardial infarction or heart failure ≥ 6 months prior to treatment initiation and in stable condition:</i></p>
<p style="text-indent:-2em;margin-left:4em;">First-dose 4-hour monitoring: Monitor patient for 4 hours following the first dose for signs and symptoms of bradycardia; assess heart rate and BP measurements every 1 hour. Obtain ECG prior to dosing and after initial 4-hour dose observation period. After the initial 4-hour monitoring, monitor until resolution (even if asymptomatic) if 4-hour postdose heart rate is &lt;45 bpm, 4-hour postdose heart rate is lowest postbaseline measurement, or 4-hour postdose ECG shows new-onset second-degree or higher atrioventricular (AV) block. Start continuous ECG monitoring if postdose symptomatic bradycardia, bradyarrhythmia, or conduction-related symptoms occur or if 4-hour postdose ECG shows new-onset second-degree or higher AV block or QTc ≥500 msec. Monitor until symptom resolution if no pharmacologic treatment is necessary. Monitor overnight with continuous ECG in a medical facility and repeat observation period for second dose if pharmacologic intervention is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients may also require overnight monitoring during treatment initiation if they have prolonged QTc interval at baseline or during 4-hour monitoring, additional risks for QT prolongation, concurrent therapy with QT prolonging agents with a known risk of torsades de pointes, concurrent therapy with drugs that slow heart rate or AV conduction, or some preexisting heart and cerebrovascular conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial monitoring procedures (ECG, heart rate, BP) must be repeated for treatment interruption of ≥4 consecutive doses during the titration or maintenance period.</p></div>
<div class="block pha drugH1Div" id="F55680800"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ponesimod, a sphingosine 1-phosphate (S1P) receptor 1 modulator, binds with high affinity to S1P receptor 1. Ponesimod blocks lymphocytes’ ability to emerge from lymph nodes, reducing the number of lymphocytes available to the CNS, which reduces inflammation (Chaudhry 2017).</p></div>
<div class="block phk drugH1Div" id="F55680801"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 160 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively metabolized via CYP450 (CYP2J2, CYP3A4, CYP3A5, CYP4F3A, and CYP4F12), non-CYP450 oxidation, and direct glucuronidation (primarily UGT1A1 and UGT2B7).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 84%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~33 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 57% to 80% (16% as unchanged drug); urine: 10% to 18% as metabolites.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522324"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ponvory | Ponvory Starter Pack</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ponvory | Ponvory styrkeserie</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ponvory</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28812220">
<a name="28812220"></a>Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. <i>Neurotherapeutics</i>. 2017;14(4):859-873. doi:10.1007/s13311-017-0565-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/28812220/pubmed" id="28812220" target="_blank">28812220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32708516">
<a name="32708516"></a>Cohan S, Lucassen E, Smoot K, Brink J, Chen C. Sphingosine-1-phosphate: its pharmacological regulation and the treatment of multiple sclerosis: a review article. <i>Biomedicines</i>. 2020;8(7):227. doi:10.3390/biomedicines8070227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/32708516/pubmed" id="32708516" target="_blank">32708516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26770667">
<a name="26770667"></a>D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. <i>Ther Adv Chronic Dis</i>. 2016;7(1):18-33. doi:10.1177/2040622315617354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/26770667/pubmed" id="26770667" target="_blank">26770667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24610328">
<a name="24610328"></a>Jamilloux Y, Néel A, Lecouffe-Desprets M, et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. <i>Neurology</i>. 2014;82(15):1307-1313. doi:10.1212/WNL.0000000000000318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/24610328/pubmed" id="24610328" target="_blank">24610328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>Eur J Neurol</i>. 2018;25(2):215‐237. doi:10.1111/ene.13536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24659797">
<a name="24659797"></a>Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. <i>J Neurol Neurosurg Psychiatry</i>. 2014;85(11):1198-1208. doi:10.1136/jnnp-2013-307282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/24659797/pubmed" id="24659797" target="_blank">24659797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ponvory.1">
<a name="Ponvory.1"></a>Ponvory (ponesimod) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; August 2023.</div>
</li>
<li>
<div class="reference">
                  Ponvory (ponesimod) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31214480">
<a name="31214480"></a>Pouzol L, Piali L, Bernard CC, Martinic MM, Steiner B, Clozel M. Therapeutic potential of ponesimod alone and in combination with dimethyl fumarate in experimental models of multiple sclerosis. <i>Innov Clin Neurosci</i>. 2019;16(3-4):22-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/31214480/pubmed" id="31214480" target="_blank">31214480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29686116">
<a name="29686116"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2018;90(17):777‐788. doi:10.1212/WNL.0000000000005347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/29686116/pubmed" id="29686116" target="_blank">29686116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20298966">
<a name="20298966"></a>Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. <i>Lancet</i>
<i>Neurol</i>. 2010;9(4):425-437. doi:10.1016/S1474-4422(10)70040-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ponesimod-drug-information/abstract-text/20298966/pubmed" id="20298966" target="_blank">20298966</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed May 7, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 131158 Version 75.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
